Highland Private Wealth Management’s Atara Biotherapeutics ATRA Stock Holding History

Highland Private Wealth Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-220	Closed	-$219K	–	127
2019 Q1	$219K	Buy	+220	New	+$204K	0.07%	103
2018 Q4	–	Sell	-220	Closed	-$227K	–	101
2018 Q3	$227K	Hold	220	–	–	0.08%	96
2018 Q2	$202K	Buy	+220	New	+$236K	0.07%	96

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Highland Private Wealth Management's ATRA Position: Q2 2019 in Review

Highland Private Wealth Management sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 220 shares — an estimated $219K sold.

Highland Private Wealth Management first reported a position in ATRA in Q2 2018 and held it in 3 quarters. The position peaked at $227K in Q3 2018. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

Highland Private Wealth Management reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
Highland Private Wealth Management sold 220 Atara Biotherapeutics shares in Q2 2019, an estimated $219K.
Highland Private Wealth Management first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 3 quarters.
Highland Private Wealth Management's Atara Biotherapeutics position peaked at $227K in Q3 2018.
116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Highland Private Wealth Management's 13F filing for Q2 2019, filed 13 Aug 2019.